Entrada Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 7, 2024
TRDA$5.25+11.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net income (loss) | $23,496 | $(6,674) |
| Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities: | ||
| Depreciation expense | 934 | 541 |
| Stock‑based compensation expense | 3,733 | 2,755 |
| Net amortization of premium (accretion of discount) on marketable securities | (2,037) | (237) |
| Changes in operating assets and liabilities: | ||
| Collaboration receivable | (71,636) | (6,297) |
| Prepaid expenses and other current assets | 2,680 | 4,339 |
| Right-of-use assets, operating leases | 2,532 | 3,332 |
| Other non-current assets | 28 | (8,633) |
| Accounts payable | (655) | 534 |
| Accrued expenses and other current liabilities | (2,522) | 4,107 |
| Income tax payable | 1,831 | — |
| Operating lease liabilities | (1,798) | (1,950) |
| Deferred revenue | 17,895 | 211,582 |
| Net cash (used in) provided by operating activities | (25,519) | 203,399 |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (838) | (1,668) |
| Purchases of marketable securities | (96,935) | (101,776) |
| Maturities of marketable securities | 123,920 | 63,000 |
| Net cash provided by (used in) investing activities | 26,147 | (40,444) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock in connection with the Vertex Agreement | — | 19,407 |
| Proceeds from exercise of stock options | 206 | 129 |
| Net cash provided by financing activities | 206 | 19,536 |
| Net increase in cash, cash equivalents, and restricted cash | 834 | 182,491 |
| Cash, cash equivalents, and restricted cash at beginning of period | 71,552 | 49,107 |
| Cash, cash equivalents, and restricted cash at end of period | $72,386 | $231,598 |
| Supplemental cash flow disclosures: | ||
| Purchases of property and equipment included in accounts payable and accrued expenses | $115 | $57 |
| Right-of-use assets surrendered as part of lease modification | $— | $7,761 |
| Transfer of deposits for equipment from operating to investing cash flows | $— | $617 |
| Vesting of options early exercised subject to repurchase | $13 | $26 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.